Imatinib mesylate, a tyrosine kinase inhibitor (TKI), specifically targets BCR-ABL, which brought a revolutionary era to the treatment of CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.